In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Valeant completes Salix purchase

This article was originally published in Scrip

Executive Summary

The Canadian firm Valeant has completed its acquisition of Salix for $173 per share, giving the deal an enterprise value of $15.8bn. Raleigh, North Carolina-based Salix is now a wholly owned subsidiary of Valeant Pharmaceuticals International. Last month Valeant upped its offer to buy Salix, prompting Endo Pharmaceuticals to withdraw from the battle to acquire the gastro-intestinal focused company. In the next six months Valeant is likely to chop $500m from the combined company's costs through "R&D rationalization" and reductions in corporate overheads. Valeant will also cut Salix's inventory levels, which Salix admitted were unusually high.



Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts